139 related articles for article (PubMed ID: 7986711)
1. Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients.
Arnér ES; Spasokoukotskaja T; Juliusson G; Liliemark J; Eriksson S
Br J Haematol; 1994 Aug; 87(4):715-8. PubMed ID: 7986711
[TBL] [Abstract][Full Text] [Related]
2. Relationship between cladribine (CdA) plasma, intracellular CdA-5'-triphosphate (CdATP) concentration, deoxycytidine kinase (dCK), and chemotherapeutic activity in chronic lymphocytic leukemia (CLL).
Albertioni F; Lindemalm S; Eriksson S; Juliusson G; Liliemark J
Adv Exp Med Biol; 1998; 431():693-7. PubMed ID: 9598154
[TBL] [Abstract][Full Text] [Related]
3. Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.
Kawasaki H; Carrera CJ; Piro LD; Saven A; Kipps TJ; Carson DA
Blood; 1993 Feb; 81(3):597-601. PubMed ID: 8094016
[TBL] [Abstract][Full Text] [Related]
4. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy.
Eriksson S; Arnér E; Spasokoukotskaja T; Wang L; Karlsson A; Brosjö O; Gunvén P; Julusson G; Liliemark J
Adv Enzyme Regul; 1994; 34():13-25. PubMed ID: 7942271
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
6. Cladribine in the treatment of chronic lymphocytic leukemia.
Robak T
Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
[TBL] [Abstract][Full Text] [Related]
7. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues.
Spasokoukotskaja T; Arnér ES; Brosjö O; Gunvén P; Juliusson G; Liliemark J; Eriksson S
Eur J Cancer; 1995; 31A(2):202-8. PubMed ID: 7718326
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine).
Robak T; Błasińska-Morawiec M; Krykowski E; Hellmann A; Konopka L
Eur J Haematol; 1997 Feb; 58(2):109-13. PubMed ID: 9111592
[TBL] [Abstract][Full Text] [Related]
9. Intracellular pharmacokinetics of 2-chlorodeoxyadenosine in leukemia cells from patients with chronic lymphocytic leukemia.
Alessi-Severini S; Gati WP; Belch AR; Paterson AR
Leukemia; 1995 Oct; 9(10):1674-9. PubMed ID: 7564508
[TBL] [Abstract][Full Text] [Related]
10. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
12. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Krykowski E; Warzocha K; Robak T
Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
[TBL] [Abstract][Full Text] [Related]
13. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
[TBL] [Abstract][Full Text] [Related]
14. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.
Robak T; Blonski JZ; Gora-Tybor J; Kasznicki M; Konopka L; Ceglarek B; Komarnicki M; Lewandowski K; Hellmann A; Lewandowski K; Moskwa A; Dmoszyńska A; Sokołowska B; Dwilewicz-Trojaczek A; Tomaszewska A; Sułek K; Całbecka M
Eur J Cancer; 2004 Feb; 40(3):383-9. PubMed ID: 14746857
[TBL] [Abstract][Full Text] [Related]
15. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
Delannoy A; Ferrant A; Martiat P; Montfort L; Doyen C; Sokal G; Michaux JL
Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):311-5. PubMed ID: 7971251
[TBL] [Abstract][Full Text] [Related]
16. 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).
Delannoy A; Martiat P; Gala JL; Deneys V; Ferrant A; Bosly A; Schieff JM; Michaux JL
Leukemia; 1995 Jul; 9(7):1130-5. PubMed ID: 7630184
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia.
Szmigielska-Kaplon A; Smolewski P; Najder M; Robak T
Ann Hematol; 2002 Sep; 81(9):508-13. PubMed ID: 12373351
[TBL] [Abstract][Full Text] [Related]
19. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia.
Saven A; Lemon RH; Kosty M; Beutler E; Piro LD
J Clin Oncol; 1995 Mar; 13(3):570-4. PubMed ID: 7884417
[TBL] [Abstract][Full Text] [Related]
20. The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Robak T
Ann Hematol; 2005 Feb; 84(2):63-70. PubMed ID: 15558283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
